Stocktoria
Greenwich LifeSciences, Inc. GLSI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-09-25
Greenwich LifeSciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $17.2M | $15.5M | $7.7M | $6.5M | $3.6M |
| Operating income | -$19.4M | -$17.6M | -$9.3M | -$8.0M | -$4.6M |
| Net income | -$19.4M | -$17.4M | -$8.9M | -$7.8M | -$4.6M |
| EPS (diluted) | $-1.43 | $-1.34 | $-0.69 | $-0.61 | — |
| Operating cash flow | -$9.9M | -$7.3M | -$6.5M | -$6.2M | -$4.3M |
| Cash & equivalents | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M |
| Total assets | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M |
| Total liabilities | $5.8M | $3.2M | $294,406 | $262,905 | $385,172 |
| Shareholders' equity | $353,217 | $908,626 | $6.7M | $13.2M | $26.8M |
Source: SEC EDGAR filings · CIK 0001799788 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.